CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
The CTS 2020 Annual Laboratory Survey is on its way to your email box. We would appreciate you takin...
The revised CTS algorithm associated with the Ortho platform is now available for review. Clie...
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....
As winter weather continues to move through parts of the US, we would like to remind you it may be n...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
CTS communications distributed on July 6th and July 20th.In working with Grifols on the availability...